Trial · NCT01127607
Outcomes27
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
21 to 27 of 27
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Impairment Rating Scale (IRS) | study endpoint- end of period II (between subjects trial) | units on a scale | MEAN | |
| SECONDARY | Weight | study endpoint- end of period II (between subjects trial) | kg | MEAN | |
| PRIMARY | Dyadic Parent-Child Interaction Coding System (DPICS) - Behavior Counts | study endpoint- end of period II (between subjects trial) | Task situation (homework vs. non-academic) was within-subjects; all participants completed both types of interactions. Medication was between subjects. | behaviors | MEAN |
| PRIMARY | Dyadic Parent-Child Interaction Coding System (DPICS) - Behavior Percentages | study endpoint- end of period II (between subjects trial) | Task situation (homework vs. non-academic) was within-subjects; all participants completed both types of interactions. Medication was between subjects. | Percentage of behaviors | MEAN |
| SECONDARY | Resting Pulse | study endpoint- end of period II (between subjects trial) | bpm | MEAN | |
| SECONDARY | Pittsburgh Side Effects Rating Scale - Percent Present for All Reported Adverse Events Occurring at a Rate of 5% or More | end of medication optimization phase/week 4 | Within-subjects analysis; data entered per dose not per subject. For example, if subject 1 took 30mg, 50mg and 70mgdoses during titration, they are recorded as three separate entries. Sample size reduces as dose increases because participants stopped at lowest acceptable dose and only moved to higher dose if they did not meet optimization criteria. | Percent of participants | NUMBER |
| SECONDARY | Adult ADHD Rating Scale Completed at the End of the Med Optimization Phase | baseline and end of med optimization phase/week 4 | Uses a within-subjects design; the same 27 participants are in both arms. | scores on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01127607/outcomes?page=2